epirubicin has been researched along with Hematologic Diseases in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (17.50) | 18.7374 |
| 1990's | 15 (37.50) | 18.2507 |
| 2000's | 16 (40.00) | 29.6817 |
| 2010's | 2 (5.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, X; Jing, T; Sun, Y; Wang, F; Xu, C; Zhang, C | 1 |
| Becerra, CR; Frenkel, EP; Tavana, D; Tran, HT; Verma, UN; Williams, NS | 1 |
| Eggemann, H; Elling, D; Harbeck, N; Janni, W; Kaufmann, M; Kiechle, M; Kümmel, S; Loibl, S; Nekljudova, V; Sommer, H; von Minckwitz, G | 1 |
| Bagnardi, V; Balduzzi, A; Bertolini, F; Cardillo, A; Colleoni, M; Goldhirsch, A; Mancuso, P; Montagna, E; Orlando, L; Scarano, E; Torrisi, R; Veronesi, P; Viale, G | 1 |
| Belmans, A; Brouwers, B; Dieudonné, A; Hatse, S; Lambrechts, D; Neven, P; Paridaens, R; Schöffski, P; van Brussel, T; Vulsteke, C; Wildiers, H | 1 |
| Cini, G; De Luca Cardillo, C; Doni, L; Fioretto, LM; Fulignati, C; Mini, E; Moretti, R; Neri, B; Pantalone, D; Quattrone, A; Ribecco, AS; Scatizzi, M; Turrini, M; Zocchi, G | 1 |
| Davidson, A; Dick, G; Pinkerton, R; Pritchard-Jones, K | 1 |
| Bonneterre, J; Catimel, G; Tubiana-Hulin, M | 1 |
| Chang, HK; Chen, MF; Chen, SC; Cheung, YC; Hsueh, S; Leung, WM; Lin, YC; Tsai, CS | 1 |
| Choi, CW; Choi, IK; Choi, JG; Kim, BS; Kim, JS; Kim, SJ; Kim, YH; Oh, SC; Park, KH; Seo, HY; Seo, JH; Shin, SW; Sul, HR; Sung, HJ; Yoon, SY | 1 |
| Avilés, A; Castañeda, C; Cleto, S; Nambo, MJ; Neri, N | 1 |
| Aravantinos, G; Fountzilas, G; Gogas, H; Kalofonos, HP; Klouvas, G; Kosmidis, P; Makatsoris, T; Papakostas, P; Pectasides, D; Tsavdaridis, D; Xanthakis, I | 1 |
| Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N | 1 |
| Cho, JY; Choi, SH; Lee, DK; Lee, KS; Lee, SI; Lee, SJ; Lim, JY; Paik, YH; Park, HJ; Yoon, DS | 1 |
| Antimi, M; Antonuzzo, L; Arcangeli, A; Banducci, S; Bellini, V; Biagioni, F; Bianchini, D; Bilancia, D; Bisagni, G; Biscottini, B; Boni, C; Bracci, R; Bravi, S; Bruno, L; Cabassi, A; Camera, S; Camisa, R; Canaletti, R; Carboni, M; Carlini, P; Carroccio, R; Cascinu, S; Catalano, G; Catalano, V; Cavalli, C; Cesari, M; Cognetti, F; Contu, A; Corgna, E; Cortesi, E; Croce, E; Dalla Mola, A; De Filippis, S; De Stefanis, M; Di Costanzo, F; Dinota, A; Enzo, MR; Farris, A; Figoli, F; Floriani, I; Foa, P; Fornarini, G; Francavilla, F; Frignano, M; Gasperoni, S; Gilli, G; Giunta, A; Grigniani, F; Ionta, MT; Italia, M; Labianca, R; Lastraioli, E; Leoni, M; Lungarotti, F; Luppi, G; Manzione, L; Masoni, L; Massidda, B; Mela, M; Messerini, L; Monzio Compagnoni, B; Muscogiuri, A; Natalini, G; Nelli, F; Nicolosi, A; Oldani, S; Olgiati, A; Olivetti, A; Orselli, G; Pandolfi, U; Papiani, G; Pazzola, A; Piga, A; Pisani Leretti, A; Porrozzi, S; Recchia, F; Romiti, A; Rondini, E; Rossetti, R; Rovei, R; Saggese, M; Sarobba, MG; Scipioni, L; Strafiuso, G; Tomao, S; Tonato, M; Torri, V; Trignano, M; Zironi, S | 1 |
| Farabegoli, G; Ganzina, F; Giovannini, M; Martoni, A; Monetti, N; Pannuti, F; Tomasi, L | 1 |
| Martini, A; Moro, E; Natale, N; Pacciarini, MA; Piazza, E; Tamassia, V | 1 |
| Canavese, G; Catturich, A; Del Mastro, L; Garrone, O; Guenzi, M; Rosso, R; Sertoli, MR; Venturini, M | 1 |
| Chevallier, B; Chollet, P; Hurteloup, P; Olivier, JP; Roche, H | 1 |
| Falk, M; Fridrik, MA; Haidinger, R; Hausmaninger, H; Klocker, J; Linkesch, W; Neubauer, M; Pont, J; Radaszkiewicz, T; Raudaschl, G; Schiller, L; Seewann, HL; Sill, H; Stöger, M | 1 |
| Aapro, M; Amadori, D; Bliss, JM; Chilvers, CE; Coombes, G; Coombes, RC; Espié, M; Ferreira, EP; Gambrosier, P; Marty, M; McArdle, C; Morvan, F; Pérez-López, FR; Richards, M; Vassilopoulos, P; Villar-Grimalt, A; Wils, J; Woods, EM | 1 |
| Horikawa, K; Okada, Y; Sano, M | 1 |
| Ashley, S; Chang, JC; Gregory, RK; Powles, TJ | 1 |
| Anker, G; Bengtsson, NO; Bennmarker, H; Bergh, J; Erikstein, B; Fornander, T; Kellokumpu-Lehtinen, P; Malmström, P; Wiklund, T; Wilking, N | 1 |
| Avanzini, P; Baldini, L; Brugiatelli, M; Carotenuto, M; Clò, V; Di Renzo, N; Dini, D; Federico, M; Gobbi, PG; Lombardo, M; Silingardi, V; Vallisa, D | 1 |
| Bianco, AR; Carlomagno, C; Casella, G; De Placido, G; De Placido, S; Ferrari, E; Fiorentino, R; Iodice, F; Lauria, R; Maffeo, A; Morabito, A; Perrone, F; Pignata, S; Ricchi, P; Tramontana, S; Varriale, E | 1 |
| Alonso, S; Armand, JP; Chouaki, N; Cortès-Funes, H; Cvitkovic, E; Fandi, A; Hasbini, A; Lianes, P; Mahjoubi, R; Raymond, E; Taamma, A | 1 |
| Bellelli, T; Bianco, AR; Carlomagno, C; De Laurentiis, M; De Placido, S; Gallo, C; Lauria, R; Limite, G; Martignetti, A; Perrone, F; Petrella, G | 1 |
| Cognetti, F; Gamucci, T; Nardi, M; Serrone, L; Zeuli, M | 1 |
| Burstein, HJ; Winer, EP | 1 |
| Biesma, B; Giaccone, G; Huisman, C; Postmus, PE; Schramel, FM; Smit, EF | 1 |
| Guaraldi, M; Martoni, A; Melotti, B; Pacciarini, MA; Pannuti, F; Riva, A | 1 |
| Dal Fior, S; Favretto, S; Gasparini, G; Panizzoni, GA; Pozza, F | 1 |
| Arian-Schad, K; Hackl, A; Heydarfadai, M; Lahousen, M; Petru, E; Pickel, H; Stettner, H | 1 |
| Coombes, RC; Cunningham, D; Haydock, A; Hickish, T | 1 |
| Bishop, J; Brodie, G; Burns, W; Coates, A; Levi, J; Raghavan, D; Schwarz, M; Snyder, R; Tattersall, M; Thomson, D | 1 |
| Bastholt, L; Bramwell, V; Buesa, J; Mouridsen, HT; Mulder, JH; Pinedo, HM; Santoro, A; Somers, R; Thomas, D; van Oosterom, AT | 1 |
| Bezwoda, WR | 1 |
| Casper, ES; Cassidy, C; Currie, V; Geller, NL; Hakes, TB; Jain, KK; Kaufman, RJ; Petroni, GR; Schwartz, W; Young, CW | 1 |
3 review(s) available for epirubicin and Hematologic Diseases
| Article | Year |
|---|---|
Chemotherapy plus estramustine for management of castration-resistant prostate cancer: meta-analysis of randomized controlled trials.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Combined Modality Therapy; Docetaxel; Epirubicin; Epothilones; Estramustine; Fatigue; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Orchiectomy; Paclitaxel; Peripheral Nervous System Diseases; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2014 |
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Fatigue; Feasibility Studies; Female; Fluorouracil; Gastrointestinal Diseases; Germany; Hematologic Diseases; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2008 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Female; Fluorouracil; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Nitriles; Organoplatinum Compounds; Paclitaxel; Tamoxifen; Thiotepa; Trastuzumab; Treatment Outcome; Triazoles; Vinblastine; Vinorelbine | 2001 |
28 trial(s) available for epirubicin and Hematologic Diseases
| Article | Year |
|---|---|
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Epirubicin; Female; Fluorouracil; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Topoisomerase II Inhibitors; Treatment Outcome | 2008 |
Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; DNA Damage; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2002 |
Paclitaxel, epirubicin and cyclophosphamide combination in first-line treatment of metastatic breast cancer: a dose escalation study.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Hematologic Diseases; Hospitalization; Humans; Middle Aged; Neutropenia; Paclitaxel; Stroke Volume; Survival Analysis; Thrombocytopenia; Treatment Outcome; Ventricular Function, Left | 2004 |
Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Comorbidity; Epirubicin; Feasibility Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Risk Assessment; Risk Factors; Severity of Illness Index; Taiwan; Treatment Outcome | 2005 |
Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antidotes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Dose-Response Relationship, Drug; Epirubicin; Female; Hematologic Diseases; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Survival Analysis; Tegafur; Tomography, X-Ray Computed; Treatment Outcome; Uracil | 2006 |
Rituximab and dose dense chemotherapy in primary breast lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Immunotherapy; Lymphoma, Non-Hodgkin; Middle Aged; Nervous System Diseases; Prednisone; Rituximab; Survival Analysis; Treatment Outcome; Vincristine | 2007 |
Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer: a Hellenic Cooperative Oncology Group (HeCOG) phase II study.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Male; Middle Aged; Severity of Illness Index; Statistics, Nonparametric; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2007 |
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Estrogens; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Paclitaxel; Peripheral Nervous System Diseases; Tamoxifen | 2008 |
Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Patient Selection; Platinum Compounds; Salvage Therapy; Severity of Illness Index; Stomach Neoplasms; Taxoids; Treatment Outcome | 2007 |
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gastrectomy; Hematologic Diseases; Humans; Immunohistochemistry; Italy; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Mucositis; Neoplasm Staging; Patient Compliance; Prognosis; Proportional Hazards Models; Stomach Neoplasms; Treatment Outcome; Vomiting | 2008 |
Cross-over study of pharmacokinetics and haematological toxicity of 4'-epi-doxorubicin and doxorubicin in cancer patients.
Topics: Aged; Doxorubicin; Epirubicin; Female; Hematologic Diseases; Humans; Injections, Intravenous; Kinetics; Male; Middle Aged; Models, Biological; Neoplasms | 1984 |
A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte colony stimulating factor as adjuvant therapy in early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Pilot Projects | 1994 |
Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Ethinyl Estradiol; Female; Fever; Fluorouracil; Hematologic Diseases; Humans; Infections; Length of Stay; Lymphatic Metastasis; Mastectomy, Modified Radical; Middle Aged; Neoplasm Staging; Pilot Projects; Remission Induction | 1993 |
CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Epirubicin; Etoposide; Feasibility Studies; Female; Folic Acid; Hematologic Diseases; Humans; Ifosfamide; Karnofsky Performance Status; Lymphoma, Non-Hodgkin; Male; Mesna; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prednisolone; Remission Induction; Risk Factors; Survival Rate; Vincristine | 1996 |
Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collab
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Nausea; Premenopause; Regression Analysis; Survival Analysis; Vomiting | 1996 |
A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Hematologic Diseases; Humans; Methotrexate; Middle Aged; Mitomycin; Mitoxantrone; Neoplasm Metastasis; Palliative Care; Prospective Studies; Survival Rate; Vincristine | 1997 |
Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Mastectomy, Radical; Middle Aged; Prognosis; Recombinant Proteins; Treatment Outcome | 1998 |
Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Heart Diseases; Hematologic Diseases; Humans; Idarubicin; Italy; Karnofsky Performance Status; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Prognosis; Proportional Hazards Models; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine | 1998 |
A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Leukocyte Count; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Recombinant Proteins; Treatment Outcome | 1999 |
Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitomycins; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Survival Rate | 1999 |
The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematologic Diseases; Humans; Neoplasm Staging; Survival Rate; Treatment Outcome | 1999 |
A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Ifosfamide; Male; Middle Aged; Nausea; Sarcoma; Soft Tissue Neoplasms; Vomiting | 2001 |
Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Treatment Outcome | 2001 |
Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial.
Topics: Adult; Aged; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Liver Neoplasms; Middle Aged; Remission Induction; Survival Rate | 1991 |
A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Heart Failure; Hematologic Diseases; Humans; Middle Aged; Nausea; Prospective Studies; Survival Rate | 1991 |
Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Doxorubicin; Drug Evaluation; Epirubicin; Female; Hematologic Diseases; Humans; Male; Middle Aged; Random Allocation; Sarcoma; Soft Tissue Neoplasms; Time Factors | 1987 |
Treatment of advanced ovarian cancer: a randomised trial comparing adriamycin or 4'epi-adriamycin in combination with cisplatin and cyclophosphamide.
Topics: Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Heart Diseases; Hematologic Diseases; Humans; Nausea; Neoplasm Staging; Nervous System Diseases; Ovarian Neoplasms; Random Allocation; South Africa | 1986 |
A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
Topics: Actuarial Analysis; Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Erythrocytes; Female; Heart Diseases; Hematologic Diseases; Humans; Middle Aged; Nausea; Physical Examination; Prospective Studies; Radionuclide Imaging; Random Allocation; Stroke Volume; Technetium | 1985 |
9 other study(ies) available for epirubicin and Hematologic Diseases
| Article | Year |
|---|---|
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Hypertension; Infusions, Intravenous; Letrozole; Mastectomy; Middle Aged; Nitriles; Paclitaxel; Prognosis; Proteinuria; Radiotherapy, Adjuvant; Triazoles | 2009 |
Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Genetic Variation; Hematologic Diseases; Humans; Middle Aged; Multidrug Resistance-Associated Proteins; Neoadjuvant Therapy; Polymorphism, Single Nucleotide; Predictive Value of Tests; Retrospective Studies | 2013 |
EVE/cyclosporin (etoposide, vincristine, epirubicin with high-dose cyclosporin)-chemotherapy selected for multidrug resistance modulation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclosporine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Kidney Diseases; Male; Neoplasms; Vincristine | 2002 |
A phase II study of 4'-epi-doxorubicin plus cis-platinum in advanced solid tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Evaluation; Epirubicin; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms | 1984 |
[Echocardiographic evaluation of cardiotoxicity induced by anthracycline therapy].
Topics: Aclarubicin; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Breast Neoplasms; Daunorubicin; Doxorubicin; Echocardiography; Epirubicin; Female; Heart; Hematologic Diseases; Humans; Male; Middle Aged; Mitoxantrone; Radionuclide Imaging; Stroke Volume | 1997 |
High-dose epirubicin for untreated patients with advanced tumours: a phase I study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Evaluation; Epirubicin; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms | 1990 |
Consolidation radiotherapy following carboplatin-based chemotherapy in radically operated advanced ovarian cancer. A pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Epirubicin; Female; Hematologic Diseases; Humans; Neoplasm Staging; Ovarian Neoplasms; Pilot Projects; Prednimustine; Survival Rate | 1991 |
Experience with intermediate-dose (110-120 mg/m2) epirubicin.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Dose-Response Relationship, Drug; Epirubicin; Female; Hematologic Diseases; Humans; Inflammation; Male; Middle Aged; Mucous Membrane; Nausea; Thrombophlebitis | 1989 |
Phase I study of epirubicin given on a weekly schedule.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Small Cell; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Epirubicin; Female; Heart Diseases; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged | 1987 |